ATE365044T1 - Verwendung eines gallensaeure-fettsaeure- konjugats oder eines gallensaeuresalz-fettsaeure- konjugats - Google Patents

Verwendung eines gallensaeure-fettsaeure- konjugats oder eines gallensaeuresalz-fettsaeure- konjugats

Info

Publication number
ATE365044T1
ATE365044T1 AT02761957T AT02761957T ATE365044T1 AT E365044 T1 ATE365044 T1 AT E365044T1 AT 02761957 T AT02761957 T AT 02761957T AT 02761957 T AT02761957 T AT 02761957T AT E365044 T1 ATE365044 T1 AT E365044T1
Authority
AT
Austria
Prior art keywords
acid
fatty acid
conjugate
bale
bile
Prior art date
Application number
AT02761957T
Other languages
German (de)
English (en)
Inventor
Tuvia Gilat
Original Assignee
Galmed Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galmed Int Ltd filed Critical Galmed Int Ltd
Application granted granted Critical
Publication of ATE365044T1 publication Critical patent/ATE365044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT02761957T 2001-04-17 2002-04-15 Verwendung eines gallensaeure-fettsaeure- konjugats oder eines gallensaeuresalz-fettsaeure- konjugats ATE365044T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL142650A IL142650A (en) 1998-04-08 2001-04-17 Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes

Publications (1)

Publication Number Publication Date
ATE365044T1 true ATE365044T1 (de) 2007-07-15

Family

ID=11075322

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02761957T ATE365044T1 (de) 2001-04-17 2002-04-15 Verwendung eines gallensaeure-fettsaeure- konjugats oder eines gallensaeuresalz-fettsaeure- konjugats
AT07002485T ATE432705T1 (de) 2001-04-17 2002-04-15 Verwendung von gallensäure- oder gallensalz- fettsäurekonjugaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07002485T ATE432705T1 (de) 2001-04-17 2002-04-15 Verwendung von gallensäure- oder gallensalz- fettsäurekonjugaten

Country Status (24)

Country Link
US (2) US7501403B2 (cg-RX-API-DMAC10.html)
EP (2) EP1379254B1 (cg-RX-API-DMAC10.html)
JP (1) JP4324706B2 (cg-RX-API-DMAC10.html)
KR (1) KR100883080B1 (cg-RX-API-DMAC10.html)
CN (1) CN1259918C (cg-RX-API-DMAC10.html)
AT (2) ATE365044T1 (cg-RX-API-DMAC10.html)
AU (2) AU2002307771B2 (cg-RX-API-DMAC10.html)
BR (1) BR0208924A (cg-RX-API-DMAC10.html)
CA (2) CA2444266C (cg-RX-API-DMAC10.html)
CY (1) CY1106853T1 (cg-RX-API-DMAC10.html)
CZ (2) CZ309042B6 (cg-RX-API-DMAC10.html)
DE (2) DE60232559D1 (cg-RX-API-DMAC10.html)
DK (2) DK1379254T3 (cg-RX-API-DMAC10.html)
EA (1) EA007565B1 (cg-RX-API-DMAC10.html)
ES (2) ES2289137T3 (cg-RX-API-DMAC10.html)
HU (1) HU230548B1 (cg-RX-API-DMAC10.html)
IL (1) IL142650A (cg-RX-API-DMAC10.html)
MX (1) MXPA03009553A (cg-RX-API-DMAC10.html)
NO (2) NO333910B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ528868A (cg-RX-API-DMAC10.html)
PL (2) PL205057B1 (cg-RX-API-DMAC10.html)
PT (2) PT1379254E (cg-RX-API-DMAC10.html)
UA (1) UA78699C2 (cg-RX-API-DMAC10.html)
WO (1) WO2002083147A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
US8975246B2 (en) * 2001-04-17 2015-03-10 Galmed Research And Development Ltd. Bile acid or bile salt fatty acid conjugates
SI2182954T1 (sl) * 2007-07-25 2019-04-30 Medizinische Universitat Graz Uporaba nor-žolčnih kislin pri zdravljenju arterioskleroze
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
HUE034551T2 (en) * 2009-01-12 2018-02-28 Biokier Inc Composition and method for treatment of diabetes
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US20120157419A1 (en) 2009-02-02 2012-06-21 Tuvia Gilat Methods and compositions for treating alzheimer's disease
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
EP2844257A4 (en) * 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
CN103571617A (zh) * 2012-07-26 2014-02-12 丰益(上海)生物技术研发中心有限公司 改进的动物油脂加工工艺
KR101702251B1 (ko) * 2012-11-29 2017-02-02 에스티팜 주식회사 신규한 소포 수송에 이용하기 위한 담즙산 올리고머 결합체 및 이의 용도
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
WO2016199137A1 (en) * 2015-06-10 2016-12-15 Galmed Research And Development Ltd. Low dose compositions of aramchol salts
LT3077047T (lt) * 2013-12-04 2019-08-26 Galmed Research & Development Ltd. Aramcholio druskos
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
WO2015186126A1 (en) * 2014-06-01 2015-12-10 Galmed Research And Development Ltd. Fatty acid bile acid conjugates for treatment of lipodystrophy
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
US11197870B2 (en) 2016-11-10 2021-12-14 Galmed Research And Development Ltd Treatment for hepatic fibrosis
CN116687850A (zh) 2022-02-24 2023-09-05 甘莱制药有限公司 包含环状膦酸酯化合物的药物组合物及其制备方法与用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859437A (en) * 1972-06-02 1975-01-07 Intellectual Property Dev Corp Reducing cholesterol levels
US3856953A (en) 1973-05-15 1974-12-24 Intellectual Property Dev Corp Method of treating fatty liver
IT1167478B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido ursodesossicolico
IT1167479B (it) * 1981-07-24 1987-05-13 Carlo Scolastico Derivati dell'acido chenodesossicolico
JPS6164701A (ja) * 1984-09-06 1986-04-03 Meito Sangyo Kk カチオン化デキストラン誘導体とポリウロン酸の高分子電解質錯体及びその利用
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5278320A (en) 1992-09-11 1994-01-11 Merck & Co., Inc. Cholesterol lowering compounds produced by directed biosynthesis
DE4432708A1 (de) * 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
IL123998A (en) * 1998-04-08 2004-09-27 Galmed Int Ltd Conjugates of bile salts and pharmaceutical preparations containing them
IL142650A (en) * 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドx受容体活性化剤

Also Published As

Publication number Publication date
NZ528868A (en) 2005-09-30
PL366585A1 (en) 2005-02-07
CY1106853T1 (el) 2012-05-23
ES2289137T3 (es) 2008-02-01
NO333910B1 (no) 2013-10-14
ES2328966T3 (es) 2009-11-19
US20040121993A1 (en) 2004-06-24
NO20034609D0 (no) 2003-10-15
US8110564B2 (en) 2012-02-07
HU230548B1 (hu) 2016-11-28
CA2444266A1 (en) 2002-10-24
US7501403B2 (en) 2009-03-10
NO335087B1 (no) 2014-09-08
CA2703688A1 (en) 2002-10-24
EP1790346A2 (en) 2007-05-30
MXPA03009553A (es) 2004-05-24
UA78699C2 (en) 2007-04-25
PT1790346E (pt) 2009-09-04
CA2703688C (en) 2012-07-31
KR20030092063A (ko) 2003-12-03
KR100883080B1 (ko) 2009-02-10
BR0208924A (pt) 2004-04-20
JP2004525962A (ja) 2004-08-26
HUP0400801A2 (hu) 2004-08-30
IL142650A0 (en) 2002-03-10
EP1379254B1 (en) 2007-06-20
AU2007200191A1 (en) 2007-02-08
HUP0400801A3 (en) 2012-09-28
NO20034609L (no) 2003-11-28
EP1379254A1 (en) 2004-01-14
PL211438B1 (pl) 2012-05-31
WO2002083147A1 (en) 2002-10-24
CZ20032710A3 (cs) 2004-04-14
PT1379254E (pt) 2007-07-10
AU2007200191B2 (en) 2008-09-04
EP1790346A3 (en) 2007-08-22
PL205057B1 (pl) 2010-03-31
CZ2008296A3 (cg-RX-API-DMAC10.html) 2004-04-14
NO20131219L (no) 2003-11-28
ATE432705T1 (de) 2009-06-15
CZ309042B6 (cs) 2021-12-22
EA007565B1 (ru) 2006-12-29
EA200301017A1 (ru) 2005-04-28
DK1790346T3 (da) 2009-10-12
CN1259918C (zh) 2006-06-21
JP4324706B2 (ja) 2009-09-02
IL142650A (en) 2007-06-03
DE60232559D1 (de) 2009-07-16
US20090149537A1 (en) 2009-06-11
DE60220775D1 (de) 2007-08-02
EP1790346B1 (en) 2009-06-03
CN1529603A (zh) 2004-09-15
DK1379254T3 (da) 2007-10-15
CA2444266C (en) 2010-07-27
CZ300489B6 (cs) 2009-06-03
AU2002307771B2 (en) 2006-10-19
DE60220775T2 (de) 2008-03-06

Similar Documents

Publication Publication Date Title
DE60220775D1 (de) Verwendung eines gallensaeure-fettsaeure-konjugats oder eines gallensaeuresalz-fettsaeure-konjugats
ATE222923T1 (de) Fettsäurederivate von gallensäure und gallensäurederivaten
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
IL206445A0 (en) Peptide conjugate of exendin-4(1-39)variant in combination with an antidiabetic agent for use in the treatment of type 2 diabetes mellitus
WO2000015211A3 (en) Compositions of chromium or vanadium with antidiabetics for glucose metabolism disorders
CA2182228A1 (en) Codrugs as a method of controlled drug delivery
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2003022210A3 (en) Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith
EP2626368A3 (en) Insulin-oligomer conjugates, formulations and uses thereof
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
EP1369419A4 (en) N-PHENYLARYLSULFONAMIDE COMPOUND, MEDICAMENT CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND AND METHODS OF PRODUCING THE SAME
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
BR9607996A (pt) Derivado de aminotetralina para o tratamento de doenças cardiovasculares
DE60238666D1 (de) Cyclohexenon derivate zur behandlung der diabetischen neuropathie
MXPA02007196A (es) Preparacion farmaceutica y metodo para el tratamiento de diabetes.
WO2000035432A3 (en) Improved viscoelastic compositions and methods of use
MX2007012991A (es) Formas solidas cristalinas y amorfas de halofenato (-) y metodoss relacionados a las mismas.
CY1108394T1 (el) Παρασκευη και διαβητικη χρηση των γιβερελινων
WO2001074852A3 (en) Protein having activity as an angiogenesis modulator
HK1127041A (en) Azetidinone derivatives for the treatment of disorders of the lipid metabolism

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1379254

Country of ref document: EP